Palonosetron and Entecavir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Palonosetron (palonosetron hydrochloride) and Entecavir (entecavir). Common drug interactions include platelet count decreased among females and agitation among males.

The phase IV clinical study analyzes what interactions people have when they take Palonosetron and Entecavir. It is created by eHealthMe based on reports of 43 people who take the same drugs from the FDA, and is updated regularly.

What is Palonosetron?

Palonosetron has active ingredients of palonosetron hydrochloride. eHealthMe is studying from 5,962 Palonosetron users. Check the latest studies of Palonosetron.

What is Entecavir?

Entecavir has active ingredients of entecavir. It is often used in hepatitis b. eHealthMe is studying from 7,354 Entecavir users. Check the latest studies of Entecavir.

On Jul, 06, 2026

43 people who take Palonosetron and Entecavir together, and have interactions are studied.

Palonosetron and Entecavir drug interactions.

What are the common drug interactions of Palonosetron and Entecavir, by gender? *:

female:

Platelet count decreased
Febrile neutropenia (fever with reduced white blood cells)
Compression fracture (fracture due to pressure caused by injury)
Myelosuppression (a decrease in the production of blood cells)
Bone marrow failure
Nausea (feeling of having an urge to vomit)
Neutropenia (an abnormally low number of neutrophils)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Pyrexia (fever)
Respiratory disorder (respiratory disease)

male:

Agitation (state of anxiety or nervous excitement)
Aphasia (damage to the parts of the brain that control language)
White blood cell count decreased
Anaemia (lack of blood)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Intervertebral disc protrusion (spinal disc protrusion)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Pyrexia (fever)
Acute respiratory failure
Decreased appetite

What are the common drug interactions of Palonosetron and Entecavir, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Febrile neutropenia (fever with reduced white blood cells)
Neutropenia (an abnormally low number of neutrophils)
Compression fracture (fracture due to pressure caused by injury)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Pyrexia (fever)
Septic shock (shock due to blood infection)
White blood cell count decreased
Anaemia (lack of blood)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Nausea (feeling of having an urge to vomit)

60+:

Biliary tract infection
Agitation (state of anxiety or nervous excitement)
Febrile neutropenia (fever with reduced white blood cells)
Leukopenia (less number of white blood cells in blood)
Myelosuppression (a decrease in the production of blood cells)
Intervertebral disc protrusion (spinal disc protrusion)
Acute respiratory failure
Bone marrow failure
Decreased appetite
Diarrhoea

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 15 people, 34.88%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 18.60%
Pain: 8 people, 18.60%
High Blood Pressure: 8 people, 18.60%
Diabetes: 8 people, 18.60%
Constipation: 7 people, 16.28%
Nausea (feeling of having an urge to vomit): 7 people, 16.28%
Fever: 6 people, 13.95%
Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 6 people, 13.95%
White Blood Cell Count Increased: 6 people, 13.95%

* Approximation only. Some reports may have incomplete information.

Do you take Palonosetron and Entecavir?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously